RET and medullary thyroid gland carcinoma: This study aimed to compare the investigator-assessed (INV) outcomes among patients with RET fusion-positive aNSCLC patients, RET-mutated MTC patients, and RET fusion-positive TC patients enrolled in LIBRETTO-001 who received 1L selpercatinib to the outcomes of patients who received standard therapies in 1L.